Tags

Type your tag names separated by a space and hit enter

A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
Antimicrob Agents Chemother. 2020 08 20; 64(9)AA

Abstract

Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on hospital mortality. We performed a single-center retrospective cohort study in a university hospital in Madrid, Spain, during March of 2020. To determine the role of steroids in in-hospital mortality, patients admitted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and treated with steroids were compared to patients not treated with steroids, and we adjusted with a propensity score for patients on steroid treatment. Survival times were compared using the log rank test. Different steroid regimens were compared and adjusted with a second propensity score. During the study period, 463 out of 848 hospitalized patients with COVID-19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) patients were treated with steroids and 67 patients were not. Global mortality was 15.1%. The median time to steroid treatment from symptom onset was 10 days (interquartile range [IQR], 8 to 13 days). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67]; hazard ratio [HR], 0.51 [95% confidence interval, 0.27 to 0.96]; P = 0.044). Steroid treatment reduced mortality by 41.8% relative to the mortality with no steroid treatment (relative risk reduction, 0.42 [95% confidence interval, 0.048 to 0.65]). Initial treatment with 1 mg/kg of body weight/day of methylprednisolone versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86]; odds ratio [OR], 0.880 [95% confidence interval, 0.449 to 1.726]; P = 0.710). Our results show that the survival of patients with SARS-CoV-2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. Rates of in-hospital mortality were not different between initial regimens of 1 mg/kg/day of methylprednisolone and glucocorticoid pulses.

Links

PMC Free PDF

Authors+Show Affiliations

Fernández-Cruz A
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain anafcruz999@gmail.com.
Ruiz-Antorán B
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Muñoz-Gómez A
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Sancho-López A
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Mills-Sánchez P
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Centeno-Soto GA
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Blanco-Alonso S
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Javaloyes-Garachana L
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Galán-Gómez A
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Valencia-Alijo Á
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Gómez-Irusta J
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Payares-Herrera C
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Morrás-Torre I
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Sánchez-Chica E
Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Delgado-Téllez-de-Cepeda L
Pharmacy Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Callejas-Díaz A
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Ramos-Martínez A
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. Pharmacy Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. Medicine Department, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Múñez-Rubio E
Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Avendaño-Solá C
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

MeSH

AgedAntiviral AgentsAzithromycinBetacoronavirusCOVID-19Cardiovascular DiseasesComorbidityCoronavirus InfectionsDiabetes MellitusDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDyslipidemiasFemaleHospitals, UniversityHumansHydroxychloroquineIntensive Care UnitsInterferonsLength of StayLopinavirMaleMethylprednisoloneMiddle AgedNeoplasmsPandemicsPneumonia, ViralRetrospective StudiesRitonavirSARS-CoV-2Survival Analysis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32571831

Citation

Fernández-Cruz, Ana, et al. "A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality." Antimicrobial Agents and Chemotherapy, vol. 64, no. 9, 2020.
Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, et al. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob Agents Chemother. 2020;64(9).
Fernández-Cruz, A., Ruiz-Antorán, B., Muñoz-Gómez, A., Sancho-López, A., Mills-Sánchez, P., Centeno-Soto, G. A., Blanco-Alonso, S., Javaloyes-Garachana, L., Galán-Gómez, A., Valencia-Alijo, Á., Gómez-Irusta, J., Payares-Herrera, C., Morrás-Torre, I., Sánchez-Chica, E., Delgado-Téllez-de-Cepeda, L., Callejas-Díaz, A., Ramos-Martínez, A., Múñez-Rubio, E., & Avendaño-Solá, C. (2020). A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrobial Agents and Chemotherapy, 64(9). https://doi.org/10.1128/AAC.01168-20
Fernández-Cruz A, et al. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Antimicrob Agents Chemother. 2020 08 20;64(9) PubMed PMID: 32571831.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. AU - Fernández-Cruz,Ana, AU - Ruiz-Antorán,Belén, AU - Muñoz-Gómez,Ana, AU - Sancho-López,Aránzazu, AU - Mills-Sánchez,Patricia, AU - Centeno-Soto,Gustavo Adolfo, AU - Blanco-Alonso,Silvia, AU - Javaloyes-Garachana,Laura, AU - Galán-Gómez,Amy, AU - Valencia-Alijo,Ángela, AU - Gómez-Irusta,Javier, AU - Payares-Herrera,Concepción, AU - Morrás-Torre,Ignacio, AU - Sánchez-Chica,Enrique, AU - Delgado-Téllez-de-Cepeda,Laura, AU - Callejas-Díaz,Alejandro, AU - Ramos-Martínez,Antonio, AU - Múñez-Rubio,Elena, AU - Avendaño-Solá,Cristina, Y1 - 2020/08/20/ PY - 2020/06/08/received PY - 2020/06/19/accepted PY - 2020/6/24/pubmed PY - 2020/9/4/medline PY - 2020/6/24/entrez KW - COVID-19 KW - mortality KW - steroids JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 64 IS - 9 N2 - Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on hospital mortality. We performed a single-center retrospective cohort study in a university hospital in Madrid, Spain, during March of 2020. To determine the role of steroids in in-hospital mortality, patients admitted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and treated with steroids were compared to patients not treated with steroids, and we adjusted with a propensity score for patients on steroid treatment. Survival times were compared using the log rank test. Different steroid regimens were compared and adjusted with a second propensity score. During the study period, 463 out of 848 hospitalized patients with COVID-19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) patients were treated with steroids and 67 patients were not. Global mortality was 15.1%. The median time to steroid treatment from symptom onset was 10 days (interquartile range [IQR], 8 to 13 days). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67]; hazard ratio [HR], 0.51 [95% confidence interval, 0.27 to 0.96]; P = 0.044). Steroid treatment reduced mortality by 41.8% relative to the mortality with no steroid treatment (relative risk reduction, 0.42 [95% confidence interval, 0.048 to 0.65]). Initial treatment with 1 mg/kg of body weight/day of methylprednisolone versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86]; odds ratio [OR], 0.880 [95% confidence interval, 0.449 to 1.726]; P = 0.710). Our results show that the survival of patients with SARS-CoV-2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. Rates of in-hospital mortality were not different between initial regimens of 1 mg/kg/day of methylprednisolone and glucocorticoid pulses. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/32571831/A_Retrospective_Controlled_Cohort_Study_of_the_Impact_of_Glucocorticoid_Treatment_in_SARS_CoV_2_Infection_Mortality_ DB - PRIME DP - Unbound Medicine ER -